Midatech pulls off a $50M IPO; Valeant takes an M&A breather;

@FierceBiotech: Bluebird posts more promising results with its rare disease therapy. Story | Follow @FierceBiotech

@DamianFierce: So the billionaire Russian oligarch who bought Watson's Nobel medal for $4.1 million is giving it back because hey. More | Follow @DamianFierce

> Nanomedicine developer Midatech priced a £32 million ($50 million) London IPO, immediately spending some of its proceeds to acquire Q Chip, a Welsh firm with a proprietary technology for sustained-release formulation. News

> PaxVax's cholera vaccine met its primary endpoint in a Phase III trial, the company said, setting the stage for an FDA application in mid-2015. Story

> Valeant Pharmaceuticals ($VRX), famed for its serial acquisitions, is planning to take a break from dealmaking to focus on its mounting debt, according to Reuters. Article

Medical Device News

@FierceMedDev: ICYMI yesterday: Edwards gains option to acquire startup CardioKinetix in $50M financing. Article | Follow @FierceMedDev

@EmilyWFierce: Stryker's OtisMed to pay more than $80M to settle DOJ case over knee replacement surgical devices. Story | Follow @EmilyWFierce

> Eurofins Scientific snaps up Boston Heart Diagnostics for $140M. Story

> Brain sensors go wireless in Brown University study. More

> Edwards looks to TAVR to convince Wall Street it can go higher after doubling in 2014. Article

Pharma News

@FiercePharma: Did Merck pay $3B too much for Cubist? Analysts weigh impact of Cubicin patent loss. Story | Follow @FiercePharma

@CarlyHFierce: AbbVie's Humira competition begins with Cadila's biosimilar launch in India. More | Follow @CarlyHFierce

> Long-term painkiller use on the rise, with more patients taking dangerous combos. Story

> J&J discount offer wins NICE over to new use for Stelara. Article

> Valeant temporarily swears off dealmaking to cut debt--and prove it's not desperate. News

Biotech Research News

> Epizyme showcases a successful preclinical lymphoma program for third target. More

> MicroRNA holds clues to predicting progression-free myeloma survival. Report

> New malaria drug unleashes an immune system assault on infected cells. Story

> Could alpha secretase offer a better approach to fighting Alzheimer's? More

> PKCƐ pathway offers a new line of attack against cancer cells. Article

Pharma Manufacturing News

> India's Zydus Cadila finds blood pressure med has embedded brown spots. Story

> Ferring preps for first U.S. plant opening as it moves to New Jersey campus. More

> FDA notches a win after Tennessee compounder pleads guilty. Report

> Meda drops Recipharm contract; plant may be forced to close. Story

> Daewoong inks deal to build $188M facility in South Korea. Article

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.